Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b Multicenter, Randomized, Placebo- Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis

Trial Profile

A Phase 2b Multicenter, Randomized, Placebo- Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 16 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Icotrokinra (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Acronyms ANTHEM-UC
  • Sponsors Janssen Research & Development; Janssen-Cilag

Most Recent Events

  • 13 Feb 2026 Status changed from active, no longer recruiting to completed.
  • 27 Oct 2025 According to Johnson and Johnson media release, Based on results from the Phase 2b ANTHEM-UC study, the company have initiated the phase 3 ICONIC-UC and ICONIC-CD Phase 2b/3 studies.
  • 27 Oct 2025 According to Johnson and Johnson media release, data from this trial will be presented at the 2025 American College of Gastroenterology Annual Scientific Meeting (ACG).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top